Newsletter

950260 - Ingenia Therapeutics Inc.(reg.s)

950260 Summary
Biopharma
Stock Price & Overview
₩15,580 -240 (-1.52%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩15,580  ≈ US$11  ·  Market cap ₩0.8tn (≈ $550m)

950260 Stock Price

14K16K18Kprev 16Kpeak 19KSep16K
52 Week Range
₩14,100₩19,290
Day Range
₩15,060₩16,290
Market Cap
₩0.8tn
P/E (TTM)
n/a
Volume
2,801,439
Shares Out
49.4M
Prev. Close
₩15,820
vs 52W High
-19.2%
Multiples use the close and the financials that were public on that date (DART), the same series as the Valuation tab — they are not vendor figures.

950260 Analysis

See all »

Nothing written yet for this company.

950260 News

See all »

No news written yet.

950260 Filings

See all »
DART

Insider / Major Shareholder Holdings Report ×7

Ownership08/25/26title translated
DART

5% Ownership Report — Large Holdings

Ownership08/25/26title translated
DART

Half-Year Report

Periodic08/19/26title translated
DART

Securities issuance results report

Filing08/04/26title translated
Korean issuers file to DART, not the SEC. Titles are translated; where kstock has read the filing the row carries the explanation.

950260 Company Profile

Ingenia Therapeutics Inc.(reg.s) does research and development in science and engineering in South Korea. It is listed on KOSDAQ, and was founded in 2018.

SectorBiopharmaEmployees
MarketKOSDAQFounded2018
Korean name인제니아테라퓨틱스(Reg.S)Head office

Similar to 950260

SymbolLast Price
185750Chong Kun Dang Pharmaceutical Corp.₩68,000
-0.3%
115180Qurient Co., Ltd.₩23,050
+17.3%
476830Rznomics, Inc.₩28,200
+6.8%
003850Boryung Corporation₩9,040
+1.6%
085660Chabiotech Co., Ltd.₩8,090
+2.1%
476060Onconic Therapeutics, Inc.₩16,440
-3.9%
041960Komipharm International Co., Ltd.₩9,710
+3.5%
317450Myungin Pharm₩44,650
+0.0%
001060JW Pharmaceutical₩27,500
+1.3%
456160G2GBIO, Inc.₩37,950
+5.7%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.